FDA 483 - University of Miami Infertility Center - September 09, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA inspected the University of Miami Infertility Center and identified significant deficiencies related to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). The facility failed to ensure donors were free of communicable disease agents, determined donor eligibility prematurely, and did not properly label HCT/Ps from ineligible donors with biohazard warnings. Two of these critical observations were repeat findings from a prior inspection, indicating persistent non-compliance.
ID · 52677459-dc6c-4c22-89d3-6bd3a161c82c